BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 10, 2023
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Charcot-Marie-Tooth Association supports Armatus advancing CMT1A
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Charcot-Marie-Tooth Association supports Armatus advancing CMT1A
Nov. 20, 2023
No Comments
The Charcot-Marie-Tooth Association (CMTA) has participated in a seed extension round for Armatus Bio Inc., an emerging biotechnology company that is advancing a unique gene therapy clinical candidate to target Charcot-Marie-Tooth (CMT) type 1A.
BioWorld Science
Financings
Gene therapy
Neurology/psychiatric
Seed